Copyright
©The Author(s) 2015.
World J Gastroenterol. Nov 7, 2015; 21(41): 11793-11803
Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11793
Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11793
Table 3 Frequency of gastrointestinal toxicities in advanced pancreatic cancer: results from main clinical trials
| Trials | Nausea | Vomiting | Diarrhea | Oral mucositis | ||||
| Any grade | G3-G4 | Any grade | G3-G4 | Any grade | G3-G4 | Any grade | G3-G4 | |
| Gemcitabine + TH-302 (240 mg/m2) (Borad et al[78]. J Clin Oncol 2014) | 39% | 10% | 24% | 6% | 28% | 3% | 18% | 0% |
| Gemcitabine + TH-302 (340 mg/m2) (Borad et al[78]. J Clin Oncol 2014) | 46% | 5% | 38% | 8% | 36% | 4% | 36% | 0% |
| Sunitinib (Yao et al[81]. N Engl J Med 2011) | 45% | 1% | 34% | 0% | 59% | 5% | 22% | 4% |
| Everolimus (Raymond et al[84]. N Engl J Med 2011) | 15% | 0% | 34% | 3% | 64% | 7% | ||
| Folfirinox (PRODIGE 4/ACCORD11 trial, Conroy et al[71]. N Engl J Med 2011) | 14.5% | 12.7% | ||||||
| Nab-paclitaxel + gemcitabine (MPACT trial, Von Hoff et al[74]. N Engl J Med 2013) | 6% | |||||||
- Citation: Aprile G, Rihawi K, De Carlo E, Sonis ST. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World J Gastroenterol 2015; 21(41): 11793-11803
- URL: https://www.wjgnet.com/1007-9327/full/v21/i41/11793.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i41.11793